Neoplastic Process

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

5 hours ago talkbio0Tagged Arch of foot, Cancer Therapeutic Procedure, CAR-T, Carl June, Dispatch Bio, Flare platform, Funding, Immunotherapy, Parker Institute for Cancer Immunotherapy, Partner in relationship, Series, Solid Neoplasm, venture

Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment

Scancell’s Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

18 hours ago talkbio0Tagged Cancer Vaccines, checkpoint inhibitors, Clinical Trials, Immunotherapy, iSCIB1 +, melanoma, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Scancell, SCOPE trial

Scancell; SCIB1; iSCIB1+; melanoma; cancer vaccine; immunotherapy; checkpoint inhibitors; clinical trial; SCOPE trial

AstraZeneca Highlights Survival Benefit for Tagrisso Combo Amid Competition in Lung Cancer

1 day ago talkbio0Tagged AstraZeneca, Benefit, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, life-extension, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Tagrisso

AstraZeneca; Tagrisso; lung cancer; Johnson & Johnson; EGFR-mutated NSCLC; overall survival; chemotherapy combination; FLAURA2 trial; life-extension benefit

Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

1 day ago talkbio0Tagged Antineoplastic Agents, Clinical Trial Design, Complete, Drops - Drug Form, Frequency of Responses, melanoma, Prices, Rejection, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

2 days ago talkbio0Tagged Accelerated, Approved, Columvi, Complete, Diffuse Large B-Cell Lymphoma, gemcitabine, genentech, oxaliplatin, Rejection, Response Letter, Roche (company), second, second-line treatment, STARGLO, Third line treatment, United States Food and Drug Administration

FDA rejection; Columvi; Roche; Genentech; diffuse large B-cell lymphoma; DLBCL; STARGLO study; second-line treatment; Complete Response Letter; gemcitabine; oxaliplatin; accelerated approval; third-line therapy

FDA Advisory Panel Rejects GSK’s Blenrep in New Combinations Over Safety, Efficacy Concerns

5 days ago talkbio0Tagged Advisory Panel, Blenrep, concerns, DREAMM, Drug Approval, Multiple Myeloma, Ocular Toxicity, Refractory Plasma Cell Myeloma, Relapsing course, Safety, SmithKline Beecham, trials, United States Food and Drug Administration

Blenrep; GSK; FDA Advisory Panel; multiple myeloma; ocular toxicity; safety concerns; DREAMM trials; drug approval; relapsed or refractory multiple myeloma

FDA Advisory Committee Votes Against GSK’s Blenrep in Multiple Myeloma

6 days ago talkbio0Tagged Advisory Committees, Clinical Trials, drug safety, Eye, Multiple Myeloma, ODAC, SmithKline Beecham, Toxicity aspects, United States Food and Drug Administration, vote

FDA Advisory Committee; Blenrep; GSK; multiple myeloma; ODAC vote; drug safety; ocular toxicity; clinical trials

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

1 week ago talkbio0Tagged Alexion, Amyloidosis, Anselamimab, AstraZeneca, Clinical trial failure, Drug Development, Infrequent, prespecified, Primary amyloidosis, Subgroup A Nepoviruses

AstraZeneca; amyloidosis; anselamimab; Phase 3 trial; clinical trial failure; prespecified subgroup; rare diseases; Alexion; AL amyloidosis; drug development

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

1 week ago talkbio0Tagged Advisory Committees, Blenrep, Drug Approval, Eye, Eye safety, Multiple Myeloma, relapsed/refractory multiple myeloma, SmithKline Beecham, Toxicity aspects, United States, United States Food and Drug Administration

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma

AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal

2 weeks ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, CD38 Antigen, Clinical Trials, Global Licensing, Ichnos Glenmark, ISB, Multiple Myeloma, Neoplasms, Phase 1 (qualifier value), Trispecific Antibody

AbbVie; Ichnos Glenmark; ISB 2001; trispecific antibody; multiple myeloma; biotech deal; CD3; BCMA; CD38; Phase 1 clinical trial; global licensing; oncology